Please Wait
Applying Filters...
menu
    • menu
    Inke SA-PSE
    News
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets

    17 Dec 2025

    // PRESS RELEASE

    Lilly to Launch Multi-Dose Weight-Loss Drug Device in US

    24 Feb 2026

    // REUTERS

    Novo's CagriSema Trial Deals Blow in Obesity drug Battle Lilly

    24 Feb 2026

    // REUTERS

    Data Compilation
    #PharmaFlow

    RM

    Contact Supplier

    Website

    International Sweetener Colloquium

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/fda-s-december-2025-opoe-list-features-784-prescription-drugs-73-otc-drugs
    Menu

    Pharmanoid

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets

    17 Dec 2025

    // PRESS RELEASE

    https://www.inke.es/news/inke-acquires-pharmanoid-a-highly-potent-api-manufacturing-site-specializing-in-ophthalmology/

    PRESS RELEASE
    17 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.